BioWorld

Nov. 13, 2007

As Big Pharma Model Falters, Biotech Rides To The Rescue

New Virulence Determinant Of Community-Associated MRSA

Infinity Regains Hedgehog Pathway Inhibitor Program

Molecular Insight Bond Deal: $150M To Advance Pipeline

Other News To Note

Synta's Elesclomol In Pivotal Study In Melanoma Patients

A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today) Read More

Clinic Roundup

ACAAI Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 5, 2025.

Highridge sells bone healing business to Avista

BioWorld MedTech

In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...

Pharma execs speak out: UK pricing rebates scare investors

BioWorld

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...